Gingival RecessionPhase 2/3NCT06643507
Evaluation of the Modified VISTA Technique Using ALB-PRF vs CTG in the Treatment of Multiple Miller Class III Recessions
A Phase 2/3 study testing Connective tissue graft and ALB-PRF in people with Gingival Recession, run by Cairo University at 1 site in Egypt.
Trial summary
treatment of miller class III RT2 gingival recession using modified vista technique using connective tissue graft vs albumin PRF Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Gingival Recession
- What is being tested?
- Connective tissue graft and ALB-PRF
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Apr 2025to 30 Jan 2027
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- 18 years old good oral hygiene
Who cannot join
- smokers patients with poor oral hygiene
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Faculty of Dentistry Cairo University
Cairo, 4240101
Cairo C.U university, 010 02159535, dentmail@dentistry.cu.edu.eg
About this study
Official title: Clinical Evaluation of the Modified VISTA Technique (M-VISTA )Using Albumin-platelet Rich Fibrin (Alb-PRF) Versus Connective Tissue Graft (CTG)in the Treatment of Multiple Miler Class III RT2 Recessions A Randomized Clinical Trial
treatment of miller class III RT2 gingival recession using modified vista technique using connective tissue graft vs albumin PRF
Read the detailed description
treatment of gingival recession is an important element in the treatment of periodontitis this study covers clinical evaluation of using the modified VISTA technique with using Albumin-PRF VS connective tissue graft in the treatment of miller class III / RT2 for root coverage outcomes
- Conditions
- Gingival Recession
- Being tested
- Connective tissue graft, ALB-PRF
- Keywords
- gingival recession, plastic surgery, soft tissue management
- Medical subject headings
- Gingival Recession
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Connective tissue graftOther
regenerative properties
ALB-PRFBiological
regenerative properties
| Study group | Role | What they receive |
|---|---|---|
| patients with gingival recession control group | Active comparator | patients with gingival recessions of miller class III /RT2 the control group will be treated with modified vista technique using connective tissue graft Receives: Other: Connective tissue graft |
| patients with gingival recession interventional group | Experimental | patients with gingival recessions of miller class III /RT2 the interventional group will be treated with modified vista technique using albumin PRF Receives: Biological: ALB-PRF |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean root coverage
primary outcome measures of mean root coverage in millimeters by UNC15 periodontal probe
Measured: 6 months
Secondary outcomes (6)
the percentage of mean root coverage
secondary outcome measures in percentage by UNC15 probe
Measured: 6 months
the percentage of complete root coverage
measures in percentage by using UNC periodontal probe
Measured: 6 months
recession depth
measures in millimeters by using UNC15 periodontal probe
Measured: 6 months
recession width
measures in millimeters by using UNC 15periodontal probe
Measured: 6 months
keratinized tissue width
measures in millimeters by using UNC15 periodontal probe
Measured: 6 months
clinical attachment level
measures by millimeters by using UNC 15 periodontal probe
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2024
- Study start20 Apr 2025
- Primary completion20 Dec 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gingival RecessionStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 26 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tamani Mahmoud Abdullah Fakhri, Cairo University
- Investigators
- Enji EA Ahmed, BDS.MDS.PHD, Study director, Cairo UniversitySarah SE Elbanna, BDS.MDS.PHD, Study director, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06643507
- Sponsor's protocol ID
- PER 3 -3 -1
- Status last verified
- Mar 2026
- First submitted
- 10 Oct 2024
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Evaluation of the Modified VISTA Technique (M-VISTA )Using Albumin-platelet Rich Fibrin (Alb-PRF) Versus Connective Tissue Graft (CTG)in the Treatment of Multiple Miler Class III RT2 Recessions A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT06643507
- Acronym / sponsor ID
- PER 3 -3 -1
- Conditions
- Gingival Recession
- Keywords
- gingival recession, plastic surgery, soft tissue management
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 26 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 20 Apr 2025 (actual)
- Primary completion
- 20 Dec 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 16 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
treatment of miller class III RT2 gingival recession using modified vista technique using connective tissue graft vs albumin PRF
Detailed description
treatment of gingival recession is an important element in the treatment of periodontitis this study covers clinical evaluation of using the modified VISTA technique with using Albumin-PRF VS connective tissue graft in the treatment of miller class III / RT2 for root coverage outcomes
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| patients with gingival recession control group | Active comparator | Other: Connective tissue graftpatients with gingival recessions of miller class III /RT2 the control group will be treated with modified vista technique using connective tissue graft |
| patients with gingival recession interventional group | Experimental | Biological: ALB-PRFpatients with gingival recessions of miller class III /RT2 the interventional group will be treated with modified vista technique using albumin PRF |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- 18 years old good oral hygiene
Key exclusion criteria (1 listed)
- smokers patients with poor oral hygiene
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Connective tissue graftregenerative properties | Other | patients with gingival recession control group |
| ALB-PRFregenerative properties | Biological | patients with gingival recession interventional group |
Primary outcome
mean root coverage
Time frame: 6 months
primary outcome measures of mean root coverage in millimeters by UNC15 periodontal probe
6 secondary outcomes
the percentage of mean root coverage
Time frame: 6 months
the percentage of complete root coverage
Time frame: 6 months
recession depth
Time frame: 6 months
recession width
Time frame: 6 months
keratinized tissue width
Time frame: 6 months
clinical attachment level
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
Related trials for Gingival Recession
Recruiting
Palatal Wound Healing After Free Gingival Graft Harvest in Diabetic Patients: A Clinical Trial
Diabetes Mellitus, Gingival Recession, Generalized
Not yet recruiting
Evaluation of the Effect of Smoking on Palatal Donor Site Tissue Profile in the Success of Connective Tissue Grafts
Soft Tissue Augmentation, Gingival Recession Localized Moderate
Active, not recruiting
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival Recession
Gingival Recession
Recruiting
Effects of Low-Level Laser Therapy and Hyaluronic Acid After Free Gingival Graft
Gingival Recession, Mucogingival Surgery
Recruiting
Impact of Root Surface Conditioning With Erythritol Air Polishing and Hand Instrumentation on Recession Coverage Using the Modified Tunnel Technique and Subepithelial Connective Tissue Graft.
Gingival Recession
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Enji EA Ahmed, BDS.MDS.PHD study director
Cairo University
Sarah SE Elbanna, BDS.MDS.PHD study director
Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Connective tissue graft and ALB-PRF in people with Gingival Recession, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tamani TM Mahmoud, BDS.MDS (Egypt:+201017874915, tamanni.mahmoud@dentistry.cu.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean root coverage (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.